Dow Corning was sued by hundreds of women in the U.S. since the storm of controversy broke out. It was believed that silicone implants were the cause of many autoimmune diseases and adverse health effects. In 1992, the silicone fillings were banned by the Food and Drug Administration banned (FDA) for cosmetic surgery in the United States. After numerous studies and the technical development of these implants, these were allowed again in 2006. In Europe, they were never banned, but there is a quality seal of approval since 2001, to ensure the quality for the patients. As a representative of Dow Corning, I would like to use a media release to present three points to the Government and the world in response to the controversy and negative publicity. Firstly, to date, 10 million women worldwide were operated on using Dow Corning’s implants. Secondly, over the years, numerous studies have concluded that the cancer risk in women with breast implants is not higher than the average population. Thirdly, Breast prostheses also do not affect the diagnosis with mammography and sonography (Wollaston, 2011). Thus, the notion that Dow Corning’s implants cause breast cancer is completely untrue and has no factual support. Early in 2011 the FDA published data of a review of work and information on the safety of silicone implants, which indicate that the probability of occurrence of a very rare form of tumor – (ALCL anaplastic large cell T-cell lymphoma) would be higher in people with implants. With reference to the fact that the very rare cases that occurred were associated with most typical symptoms, the doctors should treat these symptoms with appropriate opportunity to consider. Other special screening or precautions are not derived from these findings (Australian Foreign Press, 2011).
Even though the company has faced a lot of unnecessary problems due to the controversy and rumors related to cancer risks, I still think that Dow Corning needs to spread awareness about the risks related to implants. As a representative of Dow Corning, I suggest that certain important information needs to be used to communicate with people about risks. Implants cause the formation of fibrous capsules, which can lead to the development of capsular contracture. The actual risks of breast implants have been mentioned here. The fibrous capsule may cause painful hardening of the breasts. This is particularly dangerous and cause large implants to create a thin outer skin that covers them (Macrae, 2012). In addition, this can set the asymmetry of breasts, as a consequence of bad surgery. To correct mistakes another operation is required. This problem does not cause an increase in the breast using autograft, because this process will be used by the body’s own tissue. Violation of the sensitivity of the nipple, of wounds, swelling, and displacement of the implants are the most common hazards during the operation. When a breast implant is placed, the body reacts by wrapping a thin sheet that isolates them and is called periprosthetic capsule (AFP, 2012). For small breasts, the breast enlargement simplifies the diagnosis, but the complication rate rises in the radiation therapy after breast prosthesis implantation (Meikle, 2011).
道康宁公司被起诉在美国数百名妇女因为争论的风暴爆发。据认为，硅胶植入许多自身免疫性疾病和健康的不利影响的原因。1992，硅胶填充物的食品和药物管理局（FDA）禁止整容手术在美国。经过大量的研究，这些技术的发展，这些植入物，2006例再次允许。在欧洲，他们从来没有被禁止，但有一个密封自2001批准质量，确保患者的质量。作为道康宁公司的代表，我想用一个媒体发布至目前的三点到政府和世界针对争议和负面宣传。首先，到目前为止，全世界10000000的女性在使用道康宁的手术植入物。其次，多年来，许多研究表明，妇女的乳腺癌风险的植入物不高于平均人口。第三，乳房假体也不影响X线摄影和超声诊断（沃拉斯顿，2011）。因此，概念，道康宁的植入物引起乳腺癌是完全不真实的，没有事实支持。2011年初，FDA发布信息的审查工作，对硅的安全数据的植入物，这表明一个非常罕见的肿瘤发生的概率（间变性大细胞淋巴瘤间变性大细胞淋巴瘤）会在人与更高的植入物。根据事实发生的非常罕见的病例，最典型的症状，医生要治疗这些症状与适当的机会来考虑。其他特殊筛查或预防并没有从这些结果（澳大利亚外国出版社，2011）。
尽管公司面临了很多由于争议和癌症风险的相关传言不必要的问题，我仍然认为，道康宁需要传播相关的风险意识植入物。作为道康宁公司的代表，我建议某些重要的信息需要被用来与人有关的风险沟通。植入物引起的纤维包膜的形成，从而导致包膜挛缩的发展。乳房植入物的实际风险被提到。纤维囊可能引起疼痛的乳房硬化。这是尤其危险，引起大的植入物来创建一个薄的外层覆盖他们（麦克雷，2012）。此外，这套乳房不对称的不良后果，手术。纠正错误的另一个操作是必需的。这个问题不会导致在使用自体乳腺的增加，因为这个过程是由人体自身的组织。违反的乳头，灵敏度的伤口，肿胀，和植入物的位移是最常见的危害，在操作过程中。当乳房植入物放置，身体的反应用薄片分离，被称为假体周围胶囊（AFP，2012）。小乳房的乳房增大，简化了诊断，但并发症发生率上升在放射治疗乳房假体植入后（米克尔，2011）。
